| Literature DB >> 24966192 |
Maximilian Muenchhoff1, Philip J R Goulder2.
Abstract
The success of the immune response is finely balanced between, on the one hand, the need to engage vigorously with, and clear, certain pathogens; and, on the other, the requirement to minimize immunopathology and autoimmunity. Distinct immune strategies to achieve this balance have evolved in females and males and also in infancy through to adulthood. Sex differences in outcome from a range of infectious diseases can be identified from as early as fetal life, such as in congenital cytomegalovirus infection. The impact of sex hormones on the T-helper 1/T-helper 2 cytokine balance has been proposed to explain the higher severity of most infectious diseases in males. In the minority where greater morbidity and mortality is observed in females, this is hypothesized to arise because of greater immunopathology and/or autoimmunity. However, a number of unexplained exceptions to this rule are described. Studies that have actually measured the sex differences in children in the immune responses to infectious diseases and that would further test these hypotheses, are relatively scarce.Entities:
Keywords: gender; infections; pediatric; sex
Mesh:
Year: 2014 PMID: 24966192 PMCID: PMC4072001 DOI: 10.1093/infdis/jiu232
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226
Sex Differences in Viral, Bacterial, and Parasitic Infections in Different age Groupsa
| Pathogen/Infection | Depending Measure Reference | Age, y | Sex Bias |
|---|---|---|---|
| Viral infections | |||
| RSV | Incidence [ | 0–2 | M>F |
| Severity [ | 0–2 | M>F | |
| CMV | Severity [ | Congenital | M<F |
| Incidence [ | Congenital | M=F | |
| Adenovirus | Incidence [ | 0–14 | M>F |
| Incidence [ | >14 | M<F | |
| Coxsackievirus | Incidence [ | 0–14 | M>F |
| Incidence [ | >14 | M<F | |
| HHV-6, HHV-7 | Incidence | All | M<F |
| Measles | Protective immunity [ | All | M<F |
| Incidence [ | All | M>F | |
| Severity [ | All | M<F | |
| Mortality [ | All | M<F | |
| Complications [ | All | M>F | |
| Mumps | Incidence [ | 0–14 | M>F |
| Protective immunity [ | All | M<F | |
| Complications [ | All | M>F | |
| VZV, chickenpox | Incidence [ | 0–14 | M=F |
| VZV, chickenpox | Incidence [ | 15–24 | M<F |
| VZV, shingles | Incidence [ | >14 | M<F |
| Parvovirus B19 | Incidence [ | >2 | M<F |
| HIV | CD4+ T-cell count [ | All | M<F |
| Viral load [ | All | M<F | |
| Bacterial infections | |||
| Tuberculosis | Incidence [ | 0–1, ≥20 | M>F |
| Severity | 0–1, ≥20 | M>F | |
| Group A streptococcal pharyngitis | Incidence [ | All | M>F |
| Complications [ | All | M>F | |
| Leptospirosis | Incidence [ | <1 | M>>F |
| Incidence [ | 1–14 | M>F | |
| Incidence [ | >14 | M>>F | |
| Botulism | Incidence | All | M>F |
| Brucellosis | Incidence | All | M>F |
| Meningococcal disease | Incidence [ | 0–4 | M>F |
| Pneumococcal disease | Incidence [ | All | M>F |
| | Incidence | 0–4 | M>F |
| Pertussis | Incidence [ | All | M<F |
| Lower respiratory tract infections | Incidence [ | All | M>F |
| Severity [ | All | M>F | |
| Mycoplasma pneumoniae | Incidence [ | All | M<F |
| Parasitic infections | |||
| Leishmaniasis (cutaneous and visceral) | Incidence [ | <1 | M>>F |
| Incidence [ | 1–14 | M>F | |
| Incidence [ | >14 | M>>F | |
| Trypanosomiasis | Incidence | All | M>F |
| Chagas disease | Incidence | All | M>F |
| Schistosomiasis | Incidence [ | All | M>F |
| Lymphatic filariasis | Incidence | All | M>F |
| Onchocerciasis | Incidence | All | M>F |
Abbreviations: CMV, cytomegalovirus; F, female; HHV, human herpesvirus; HIV, human immunodeficiency virus; M, male; RSV, respiratory syncytial virus; VZV, varicella-zoster virus.
a Information has been extracted from epidemiological surveillance data published by the World Health Organization, the Centers for Disease Control and Prevention, the European Centre for Disease Prevention and Control, the Japanese Infectious Disease Surveillance Center, and specific references as indicated.